Paion (DE: PA8)

Last close As at 22/05/2024

2.46

0.00 (0.00%)

Market capitalisation

163m

Edison Investment Research is terminating coverage on Paion. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

View More

Healthcare | Update

Paion — GA data enable an application for surgical use

Healthcare | QuickView

Paion — Commercialisation of remimazolam underway

Healthcare | research

Paion — Remimazolam: Three major approvals

Healthcare | Update

Paion — ByFavo – poised for autumn US launch

Financials

Edison Investment Research is terminating coverage on Paion. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Research

Update

Healthcare

Paion — Progressing towards filings in US and Japan

Update

Healthcare

Paion — Remimazolam set for commercialisation in 2019

Update

Healthcare

Paion — Positive data in bronchoscopy Phase III

Update

Healthcare

Paion — On track for two filings by mid-2018

Update

Healthcare

Paion — On track to file in US and Japan by mid-2018

research

Healthcare

Paion — Positive data in high-risk patients

Outlook

Healthcare

Paion — Update 21 November 2016

Update

Healthcare

Paion — Update 5 July 2016

Update

Healthcare

Paion — Update 17 May 2016

Update

Healthcare

Paion — Update 16 February 2016

Update

Healthcare

Paion — Update 9 February 2016

Update

Healthcare

Paion — Update 17 November 2015

thematic

Healthcare

Machine learning in drug development

cell DNA double helix

thematic

Healthcare

Cell and gene therapies

thematic

Healthcare

Drug delivery platforms

thematic

Healthcare

Neuroscience comeback

thematic

Consumer

IPO apocalypse

thematic

Healthcare

Oncology ABCs (part two) – vaccines: niche no longer

thematic

TMT

ESG, moving beyond the box tick

thematic

Healthcare

Artificial intelligence in drug discovery

thematic

Healthcare

Edison Exhibits- antibiotic development

thematic

Healthcare

The next wave in AMD

thematic

Healthcare

Cannabinoid Therapies- The coming retail wave

thematic

Healthcare

Cannabinoid Therapies- Therapeutics turning a corner

thematic

Healthcare

Drug pricing – Market access and reimbursement

thematic

Healthcare

The diagnostics sector

thematic

Healthcare

ASCO 2017

thematic

Consumer

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

Energy & Resources

ASX Spotlight Conference – London, 6 March 2014

thematic

Energy & Resources

ASX Small to Mid Caps Conference – London, 7 March 2013

thematic

Healthcare

Edison healthcare quarterly: Boom times for US biotech

thematic

Healthcare

Edison healthcare quarterly: Crisis? What crisis?